Enterobacterales

Venatorx Announces Presentation of Analysis of Cefepime-Taniborbactam in vitro Activity against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, PWC, Infection, Incidence, CRE, Gram-negative bacteria, Extended-spectrum penicillin, Bacteria, GN, Risk, Escherichia coli, UICC, Enterobacterales, Ceftolozane/tazobactam, Cancer, MD Anderson Cancer Center, Pseudomonas aeruginosa, MDR, University, Ceftazidime/avibactam, Medication, ESBL, Serine, Patient, AMR, Pharmaceutical industry

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.
  • The bacterial isolates tested included Extended Spectrum β-lactamase (ESBL) producing Enterobacterales and Carbapenem Resistant Enterobacterales (CRE) isolates, and MDR Pseudomonas aeruginosa.
  • In the study, cefepime-taniborbactam demonstrated higher in vitro activity than the tested comparators.
  • While cefepime-taniborbactam has not yet been approved for clinical use, only 3 of the 270 isolates (1.1%; 2 CRE Escherichia coli and 1 MDR P. aeruginosa) were found to be resistant to cefepime-taniborbactam at its provisional breakpoint.

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Retrieved on: 
Wednesday, October 11, 2023
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Nursing care plan, FCCP, Philippe Ciais, Food, Doctor of Philosophy, Division, Multidrug-resistant bacteria, Development, MD, Synergy, Infection, Meropenem, Therapy, Sulbactam, Combination, Food and Drug Administration, Fungal infection, Cefepime, Pseudomonas aeruginosa, FIDSA, Doctor of Pharmacy, Hartford Hospital, Research, Pharmaceutical industry, Vaccine, Antibiotics, Imipenem, Enterobacterales

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their portfolio of U.S. Food and Drug Administration (FDA)-approved critical care and infectious disease therapies at IDWeek 2023, October 11-15, held in Boston, MA.

Key Points: 
  • Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their portfolio of U.S. Food and Drug Administration (FDA)-approved critical care and infectious disease therapies at IDWeek 2023, October 11-15, held in Boston, MA.
  • XACDURO is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
  • In addition, four company-sponsored research studies on XACDURO will also be presented by the company’s research partners in poster sessions.
  • “Antibiotic-resistant pathogens are one of the most significant and challenging threats to healthcare providers on the frontlines of infectious disease care,” said Margaret Koziel, MD, Chief Medical Officer, Innoviva Specialty Therapeutics.

Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US

Retrieved on: 
Monday, August 14, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, MBL, Enterobacterales, IDSA, JMI, MBL deficiency, Medication, SBL, Genetically modified bacteria, Hospital, Publication, IHMA, Johns Hopkins University, Patient, Viral, Klebsiella, CRE, Epidemiology, Vaccine, Pharmaceutical industry, Asia-Pacific Telecommunity band plan

When looking deeper at the specific contribution from carbapenemase families, metallo-beta-lactamases (MBLs) were the most frequently identified carbapenem resistance mechanism.

Key Points: 
  • When looking deeper at the specific contribution from carbapenemase families, metallo-beta-lactamases (MBLs) were the most frequently identified carbapenem resistance mechanism.
  • In the U.S. and Canada, MBLs were found in 15.5% of all CRE isolates in 2018-2019, or approximately 1 out of every 7 CRE isolates.
  • This represents a 300% increase from the 2012-17 period when only 5% of CRE isolates expressed MBLs in the US and Canada.
  • [4] of Johns Hopkins University analyzed consecutive CRE clinical isolates collected from unique patients at 3 US hospitals from 2016-2021.

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

Retrieved on: 
Thursday, February 10, 2022
Adoption, Nadine Opgen-Rhein, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Private Securities Litigation Reform Act, Goal, Precision medicine, Technology, Public health, Gene, COVID-19, Gram-negative bacteria, Whole genome sequencing, AST, Aminoglycoside, Drug resistance, Journal, Beta-lactam, Enterococcus faecalis, Lancet, NGS, PPA, Infection, Securities Act of 1933, Culture, Antibiotic sensitivity testing, Infectious Diseases Society of America, WGS, Drug of last resort, Nasdaq, Pseudomonas aeruginosa, Detection, GLOBE, European Journal of Clinical Microbiology & Infectious Diseases, Bacteria, AMR, NPA, Informatics, Colistin, Solution, Security (finance), Securities Exchange Act of 1934, Fatality, FDA, Hospital, IDSA, Vaccine, MD, Enterobacterales

The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing (WGS), organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture.

Key Points: 
  • The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing (WGS), organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture.
  • In this publication titled Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates 1, the authors note that associating the AMR markers with not susceptible phenotypic results is a key differentiator of the FDA-cleared Acuitas AMR Gene Panel compared to other molecular panels that simply detect the presence or absence of a gene.
  • Several clinical cases illustrating the potential utility of the Acuitas AMR Gene Panel were presented during a recent webinar titled Discovering the FDA-cleared Acuitas AMR Gene Panel: Building a Case for Clinical Utility .
  • This press release includes statements regarding the publication of results of a recent study of the Acuitas AMR Gene Panel.

LexaGene Finalizes Design of Pneumonia Panel

Retrieved on: 
Monday, November 1, 2021
Ethos, Fungus, CMY, Escherichia coli, Diagnosis, Proning, PCR, Hospital, Degenerative disease, TEM, LXG, MecA, Phycita, Infection, Histoplasma, Patient, Founder, TETS, SHV, Pneumonia, Staphylococcus, OTCQB, Enterobacterales, Time-invariant system, Enterobacter, CEO, Skin, Bacteria, Veterinarian, Animal, DVM, Teto, GLOBE, Tetje Mierendorf, Bordetella, Doctor of Philosophy, ONC, Ear, Vaccine, Pharmaceutical industry

In June 2021, LexaGene and Ethos Discovery partnered to develop a pneumonia panel to expand the utility of the MiQLab in veterinary diagnostics.

Key Points: 
  • In June 2021, LexaGene and Ethos Discovery partnered to develop a pneumonia panel to expand the utility of the MiQLab in veterinary diagnostics.
  • Since then, LexaGene has been working closely with Ethos Discovery to design and validate a panel for rapidly determining the cause of pneumonia while simultaneously screening for antimicrobial resistance factors that should be taken into account when treating such infections in companion animals.
  • As a next step, Ethos Discovery will conduct a clinical evaluation of the pneumonia panel on their purchased MiQLab.
  • The MiQLab Pneumonia Panel includes 13 assays targeting bacteria and 4 assays targeting fungi, plus 19 assays targeting antimicrobial resistance genes.